



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mark T. Bilodeau et al.

Serial No. 10/677,687

Filed: October 2, 2003

For: TYROSINE KINASE INHIBITORS

Art Unit: _____

Examiner: _____

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97**

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

4. Pursuant to the waiver by the Office of the requirement under 37 CFR 1.98 (a)(2)(i) dated July 11, 2003, if the filing date of this application is after June 30, 2003, copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Sana Seimstadt Date 12/23/03

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:


RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE
09/990,473	November 21, 2001	20721Y

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☒ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: Matthew A. Leff

Attorney _____ For Applicant(s)

Reg. No. 50,149

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-1404

Date: December 23, 2003

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/677,687
---------------------------	------------

Filing Date	October 2, 2003
--------------------	-----------------

First Named Inventor	Mark T. Bilodeau et al.
-----------------------------	-------------------------

Group Art Unit

Examiner Name

Attorney Docket Number 20721 YCA

Sheet

1

of

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
		EPO	1040831 A2		Pfizer Products Inc.	04/10/2000
		PCT	WO 95/33750		Pfizer Inc.	12/14/1995
		PCT	WO 00/62778		Bristol-Myers Squibb Co.	10/26/2000
		PCT	WO 00/39101		AstraZeneca	07/06/2000
		PCT	WO 99/65884		Bristol-Myers Squibb Co.	06/11/1999

Examiner
Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003


Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			COMPLETE IF KNOWN	
			Application Number	10/677,687
			Filing Date	October 2, 2003
			First Named Inventor	Mark T. Bilodeau et al.
			Group Art Unit	
			Examiner Name	
Sheet	2	of	Attorney Docket Number	20721 YCA

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		J. Rak et al. Cancer Research, 55:4575-4580, 1995
		G. Gasparini and A.L. Harris, J. Clin. Oncol., 1995, 13:765-782
		M. Toi et al., Japan. J. Cancer Res., 1994, 85:1045-1049
		A.J. Dickinson et al., Br. J. Urol., 1994, 74:762-766
		L.M. Ellis et al., Surgery, 1996, 120(5):871-878
		J.K. Williams et al., Am. J. Surg., 1994, 168:373-380
		A. Amirkhosravi et al., Platelets, 10:285-292 (1999)
		S.P. Gunningham, et al., Can. Research, 61: 3206-3211 (2001)
		A. Giatromanolaki et al., J. Pathol. 2001; 194:101-108
		Michael Detmar, J. Dermatological Sci., 24 Suppl. 1, S78-S84 (2000).
		Hasegawa et al., Skeletal Radiol., Vol. 28, pp.41-45, 1999
		Brockelsby et al., Laboratory Investigation 79:1101-1111 (September 1999)
		Paul et al., Nature Med 7:222-227 (2001).
		Matsuyama et al., J. Neurol. Sci. 186:75-79 (2001)
		van der Flier et al., J. Infectious Diseases, 183:149-153 (2001)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO		COMPLETE IF KNOWN	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Application Number	10/677,687
		Filing Date	October 2, 2003
		First Named Inventor	Mark T. Bilodeau et al.
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	20721YCA
Sheet	3	of	

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Stephen K. Smith, Trends in Endocrinology & Metabolism, Vol. 12, No. 4, pp. 147-151, May/June 2001
		Levis et al., Blood, Vol. 98, No. 3, pp.885-887 (2001)
		Rajesh K. Jain, Nature Medicine, Vol. 7. No. 9, pp. 987-989 (September 2001)
		Giulio Jori, Lasers Med. Sci., 1990; 5: 115-120
		Chuannong Zhou, J. Photochem. and Photobiol. 1989; 3: 299-318
		Hendrich et al., Knee Surg Sports Traumatol Arthroscopy 5: 58-63 (1997).
		Hall et al., Am J Hum Genet 61:785-789, 1997
		Li et al., Gene Therapy, 1998; 5:1105-13
		Fathallah-Shaykh et al., J Immunol 2000; 164:217-222
		Dougherty et al., J. Natl. Cancer Inst., 1998, 90(12): 889-905
		Van Bruggen et al., J. Clin. Invest., 104:1613-1620 (1999)
		Gerber et al., Nature Medicine, Vol. 5, No. 6, pp.623-628, 1999
		David A. Greenberg, Drug News Perspect 11(5):265-270 (1998)
		Nakagawa et al., FEBS Let. 473:161-164 (2000)
		Peter Traxler, Exp. Opin. Ther. Patents 8 (12) 1599-1625(1998).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

[illegible]

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003